Validating the NIH LDL-C equation for provincial implementation in Alberta

被引:0
|
作者
Higgins, V. [1 ,2 ]
Garcia, L. [2 ]
Gifford, J. L. [3 ,4 ]
Volodko, N. [1 ,2 ]
Beriault, D. R. [5 ,6 ]
Parker, M. L. [1 ,2 ]
Estey, M. P. [1 ,2 ]
Proctor, D. T. [1 ,2 ]
Ismail, O. Z. [1 ,2 ]
机构
[1] DynaLIFE Med Labs, Edmonton, AB, Canada
[2] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada
[3] DynaLIFE Med Labs, Calgary, AB, Canada
[4] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada
[5] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[6] St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON, Canada
关键词
LDL-C; Triglycerides; Lipid panel; Cardiovascular disease; DENSITY-LIPOPROTEIN CHOLESTEROL; SOCIETY;
D O I
10.1016/j.clinbiochem.2023.110678
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: LDL-C, a cardiovascular disease risk assessment biomarker, is commonly calculated using the Friedewald equation. The NIH equation overcomes several limitations of the Friedewald equation. Consistent with the Canadian Society of Clinical Chemists (CSCC) lipid reporting recommendations, we assessed the NIH LDL-C equation in Alberta prior to its provincial implementation.Methods: 1-year (01/01/2021-12/31/2021) of lipid results (n = 1,486,584 after data cleaning) were obtained from five analytical instrument groups used across Alberta. Analyses were performed on all data and after separating by age, analytical instrument group, and fasting status. The correlation between Friedewald- and NIHcalculated LDL-C and between Friedewald- and NIH-calculated LDL-C difference and each lipid parameter, was determined. The frequency of unreportable/inaccurate LDL-C results was compared between the two equations. The concordance between the two equations and with non-HDL-C was determined at LDL-C thresholds. Lastly, LDL-C calculated by Friedewald, NIH, and Martin-Hopkins equations was compared to density-gradient ultracentrifugation. Results: Friedewald- and NIH-calculated LDL-C exhibit the strongest correlation when triglycerides <= 4.52 mmol/ L. The difference between Friedewald- and NIH-calculated LDL-C increases with decreasing LDL-C concentration. The NIH equation yields fewer inaccurate results (0.35 % vs. 22.0 %). The percent agreement between equations was > 96 % at all LDL-C thresholds, suggesting most patients will not require treatment changes. NIH-calculated LDL-C exhibited better agreement with non-HDL-C when triglycerides <= 9.04 mmol/L and better correlated with LDL-C measured by ultracentrifugation (r(2) = 0.926 vs. 0.775 (Friedewald) and 0.863 (Martin-Hopkins)). Results were consistent across age, analytical instrument group, and fasting status.Conclusions: Our findings demonstrate the benefits of implementing the NIH equation across Alberta.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Reducing LDL-C - Treating to target
    Kritharides, L
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 94 - 94
  • [22] Is very low LDL-C harmful?
    Faselis, Charles
    Imprialos, Konstantinos
    Grassos, Haris
    Pittaras, Andreas
    Kallistratos, Manolis
    Manolis, Athanasios
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (31) : 3658 - 3664
  • [23] Calculated LDL-C: Time to Move On?
    Cartier, Louis-Jacques
    Chen, Yu
    Canales, Donaldo D.
    CANADIAN JOURNAL OF CARDIOLOGY, 2023, 39 (03) : 353 - 354
  • [24] Lipoprotein(a) and LDL-C The Relevance of Equivalence
    Morris, Pamela B.
    Narula, Jagat
    Tsimikas, Sotirios
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (21) : 2011 - 2013
  • [25] Performance of equations for calculated LDL-C in hypertriglyceridaemia: Which one correlates best with directly measured LDL-C?
    Steyn, Nicolene
    Rossouw, H. Muller
    Martins, Janine
    Pillay, Tahir S.
    CLINICA CHIMICA ACTA, 2023, 545
  • [26] Extensive Evidence Supports the Martin-Hopkins Equation as the LDL-C Calculation of Choice
    Grant, Jelani K.
    Kaufman, Harvey W.
    Martin, Seth S.
    CLINICAL CHEMISTRY, 2024, 70 (02) : 361 - 367
  • [27] EVALUATION OF A DIRECT LDL-CHOLESTEROL (LDL-C) ASSAY
    CHESLER, R
    COSTELLO, R
    CSAKO, G
    CLINICAL CHEMISTRY, 1995, 41 (06) : S141 - S141
  • [28] Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
    Clem, James R.
    Strain, Joe D.
    Farver, Debra K.
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2010, 3 : 1 - 11
  • [29] In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months
    Clark, Jennifer
    Montori, Victor
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (04) : JC18 - JC18
  • [30] IMPORTANCE OF BASELINE LDL-C IN THE ASSOCIATION BETWEEN LDL-C LOWERING AND CARDIOVASCULAR RISK: A META-REGRESSION ANALYSIS
    Hawe, E.
    Meleth, S.
    Wolowacz, S.
    Bilitou, A.
    ATHEROSCLEROSIS, 2022, 355 : E266 - E267